ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Colchicine: An Ancient Drug with Modern Uses

Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH  |  August 11, 2021

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryColchicinedrug treatmentGoutinflammation

Therapeutic Drug Monitoring May Offer Little Benefit to Patient Remission Rates During Infliximab Induction Therapy

Lara C. Pullen, PhD  |  August 9, 2021

Although rheumatologists prescribe tumor necrosis factor inhibitors (TNFi’s) to treat several rheumatic diseases, they recognize immunogenicity influences the efficacy and safety of TNFi’s. Example: The formation of anti-drug antibodies can affect infusion reactions and cause low-serum drug levels and therapeutic failure. The induction phase is a period of high incidence of immunogenicity, and observational data…

Filed under:Drug Updates Tagged with:infliximabtherapeutic drug monitoringTNF inhibitorTNFitumor necrosis factor inhibitor (TNFi)

Georgia Bonney

Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

Larry Beresford  |  August 6, 2021

As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.

Filed under:Legislation & AdvocacyPractice Support Tagged with:Advocacyprior authorization

Early & Long-Term Remission of Spondyloarthritis

Jason Liebowitz, MD, FACR  |  July 16, 2021

Filip Van den Bosch, MD, described his strategies for caring for patients with SpA and the possibility of achieving disease inactivity.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting Reports Tagged with:EULARpatient carespondyloarthritis

Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  June 29, 2021

In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:psoriatic arthritis

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARoutcomeOutcome measurespsoriatic arthritis

Case Report: Does a Young Woman with Gitelman Syndrome Have Gout?

Rebecca Lindsey Weiner, DO, & Ann K. Rosenthal, MD, FACP  |  June 14, 2021

Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:case reportGitelman SyndromeGout

Anze Furlan / SHUTTERSTOCK.COM

How Immunosuppression May Affect COVID-19 Vaccine Response

Ruth Jessen Hickman, MD  |  June 13, 2021

Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

Filed under:Conditions Tagged with:COVID-19immunosuppressionvaccination

Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2021

Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptinjection pensyringeYLB113-002

Case Report: A Mycobacterium kansasii Infection

Kayleigh A. Sullivan, MD, MA, MPH, Nicole Orzechowski, DO, & Elizabeth A. Talbot, MD  |  May 13, 2021

A 61-year-old white woman presented to our rheumatology clinic in New England to establish care in early June 2018, following a move from Texas. She reported a medical history of inflammatory bowel disease, uveitis and sero­negative inflammatory arthritis, which was difficult to control and required the use of multiple medications. At her initial visit, she…

Filed under:Conditions Tagged with:case reportInfectionMycobacterium kansasiinontuberculous mycobacterium (NTM)

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 56
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences